4SC expands domatinostat combo testing
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 990 entries already.
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the […]
A new test based on tumour organoids can predict how patients with advanced colorectal cancer (CRC) respond to chemotherapy treatment.
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer-drug conjugates.
Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies Novo Nordisk A/S tries to get foothold in the emerging hemophilia A gene therapy market.
Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
German researchers have unraveled the mechanism of a ADEPs, a novel class of antibiotics, allowing pharmacological optimisation.
A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.